The Indian Express edit page today carries a column I wrote on fixed dose combinations (FDCs) post the Lancet article. For the record, the Lancet shone the light on a plethora of FDCs of the diabetes drug metformin with others that, they believe, have no rationale to be on the market. I have used the … Continue reading Here I go again. My column on fixed dose combos for the Indian Express #pharma #safety
Tag: indian express
Think deeper about drugs affordability : my column in the Indian Express
My latest column in The Indian Express addresses the question of drug affordability. In this column, I have argued that the new Drug Price Control Order (DPCO), soon to complete a year in existence, while a major preoccupation with mandarins and managers alike in the last few months, is not a panacea for affordability. I … Continue reading Think deeper about drugs affordability : my column in the Indian Express
Stop tinkering with FDI norms : my column in the Indian Express
Today's edition of the Indian Express has an edit piece that I have authored on why the government should stop repeatedly tinkering with India's foreign direct investment (FDI) policy for pharmaceuticals. In this piece I have argued that there is no connection between the availability of essential medicines and the FDI policy and that this … Continue reading Stop tinkering with FDI norms : my column in the Indian Express
The pioglitazone ban : My column in The Indian Express
Today's edit page of The Indian Express has my column on the Indian drugs regulator's decision to ban pioglitazone, an anti-diabetes drug reportedly taken by 30 lakh patients. I have argued that India is paying for its historically casual attitude to pharmacovigilance or tracking drug safety. I have reproduced parts of the IE column below … Continue reading The pioglitazone ban : My column in The Indian Express
Apothecurry 